Overview
- Population
Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).
Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
These 5 cohorts will be subject to standardized clinical monitoring.
Description
This study is proposed by the Rheumatology and Pediatrics departments of the 3 French-speaking Universities.
The first objective will be to include a progressive number of new young patients (≤ 50 years) in order to optimize and standardize care and clinical response objectives. The number of 25% of new incident cases will be sought with an increase of 20% each year during the 5 to 10 years of this project.
Population: JIA, RA/UA, SLE, dSS (American Congres of Rheumatology criteria). Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
These 5 cohorts will be subject to standardized clinical monitoring and specific objectives that will make it possible to analyze the number of patients with a good control of the disease and/or a clinical remission, defined according to the international criteria.
Eligibility
Inclusion Criteria:
- Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria).
- Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
Exclusion Criteria:
- Treated for > 3 months
- > 50 years old